KR970707153A - 카텝신 02 프로테아제(cathepsin 02 protease) - Google Patents

카텝신 02 프로테아제(cathepsin 02 protease)

Info

Publication number
KR970707153A
KR970707153A KR1019970702787A KR19970702787A KR970707153A KR 970707153 A KR970707153 A KR 970707153A KR 1019970702787 A KR1019970702787 A KR 1019970702787A KR 19970702787 A KR19970702787 A KR 19970702787A KR 970707153 A KR970707153 A KR 970707153A
Authority
KR
South Korea
Prior art keywords
cathepsin
protein
nucleic acid
recombinant
antibody
Prior art date
Application number
KR1019970702787A
Other languages
English (en)
Other versions
KR100473219B1 (ko
Inventor
브뢰메 디터
오카모토 캐틀린
Original Assignee
다니엘 에이치. 페트리
아리스 파마슈티칼 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970707153(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/330,121 external-priority patent/US5736357A/en
Application filed by 다니엘 에이치. 페트리, 아리스 파마슈티칼 코포레이션 filed Critical 다니엘 에이치. 페트리
Publication of KR970707153A publication Critical patent/KR970707153A/ko
Application granted granted Critical
Publication of KR100473219B1 publication Critical patent/KR100473219B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 카텝신 02 단백질, 핵산, 및 항체에 관한 것이다.

Description

카텝신 02 프로테아제(CATHEPSIN 02 PROTEASE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 제1도에 도시된 아미노산 서열(서열번호 2)과 약 95%이상이 상동인 아미노산 서열을 갖는 재조합 사람 카텝신 02 단백질.
  2. 제1항에 있어서, 제1도에 도시된 아미노산 서열(서열번호 2)를 가짐을 특징으로 하는 재조합 사람 카텝신 02 단백질.
  3. 제1항에 있어서, prepro카텝신 02 단백질을 포함함을 특징으로 하는 재조합 카텝신 02 단백질.
  4. 제1항에 있어서, pro카텝신 02 단백질을 포함함을 특징으로 하는 재조합 카텝신 02 단백질.
  5. 제1항에 있어서, 카텝신 02 단백질의 pro 부분을 포함함을 특징으로 하는 재조합 카텝신 02 단백질.
  6. 사람 카텝신 02 단백질을 코드화하는 재조합 핵산.
  7. 제6항에 있어서, 제1도에 도시된 핵산 서열(서열번호 1)과 하이브리드를 형성하는 재조합 핵산.
  8. 제6항에 있어서, 상기 카텝신 02 단백질이 prepro 카텝신 02 단백질을 포함함을 특징으로 하는 재조합 핵산.
  9. 제6항에 있어서, 상기 카텝신 02 단백질이 pro 카텝신 02 단백질을 포함함을 특징으로 하는 재조합 핵산.
  10. 제6항에 있어서, 카텝신 02 단백질이 pro 카텝신 02 단백질을 포함함을 특징으로 하는 재조합 핵산.
  11. 제7항에 있어서, 제1도에 도시된 서열(서열번호 1)과 약 95%이상이 상동인 서열을 갖는 DNA를 포함함을 특징으로 하는 핵산.
  12. 제8항에 있어서, 제1도에 도시된 서열(서열번호 1)을 가짐을 특징으로 하는 재조합 핵산.
  13. 사람 카텝신 02 단백질을 코드화하는 DNA에 작동가능하게 결합된 전사 및 해독 조절 DNA를 포함하는 발현 벡터.
  14. 사람 카텝신 02 단백질을 코드화하는 핵산을 포함하는 발현 벡터로 형질전환시킨 숙주 세포.
  15. a) 카텝신 02 단백질을 코드화하는 핵산을 포함하는 발현 벡터로 형질전환시킨 숙주 세포를 배양하는 단계; 및 b) 상기 핵산을 발현시켜 카텝신 02 단백질을 재조하는 단계를 포함하는 사람 카텝신 02 단백질의 제조 방법.
  16. 카텝신 02 단백질과 결합하는 항체.
  17. 제16항에 있어서, 상기 카텝신 02 단백질이 성숙한 카텝신 02 단백질임을 특징으로 하는 항체.
  18. 제16항에 있어서, 상기 카텝신 02 단백질이 pro카텝신 02 단백질임을 특징으로 하는 항체.
  19. 제16항에 있어서, 상기 카텝신 02 단백질이 카텝신 02 단백질임의 pro 부분임을 특징으로 하는 항체.
  20. 제16항에 있어서, 단클론성 항체임을 특징으로 하는 항체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702787A 1994-10-27 1995-10-26 카텝신o2프로테아제 KR100473219B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/330,121 US5736357A (en) 1994-10-27 1994-10-27 Cathespin O protease
US08/330,121 1995-10-02
US08/536,861 1995-10-02
US08/536,861 US6544767B1 (en) 1994-10-27 1995-10-02 Cathespin O2 protease
PCT/US1995/013820 WO1996013523A1 (en) 1994-10-27 1995-10-26 Cathepsin o2 protease

Publications (2)

Publication Number Publication Date
KR970707153A true KR970707153A (ko) 1997-12-01
KR100473219B1 KR100473219B1 (ko) 2005-05-16

Family

ID=26987129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702787A KR100473219B1 (ko) 1994-10-27 1995-10-26 카텝신o2프로테아제

Country Status (15)

Country Link
US (2) US6544767B1 (ko)
EP (1) EP0783527B1 (ko)
JP (1) JP3670666B2 (ko)
KR (1) KR100473219B1 (ko)
CN (1) CN1148382C (ko)
AT (1) ATE317441T1 (ko)
AU (1) AU711810B2 (ko)
CA (1) CA2203765C (ko)
DE (1) DE69534778T2 (ko)
ES (1) ES2256849T3 (ko)
FI (1) FI971777A (ko)
HU (1) HU220960B1 (ko)
NO (1) NO971875L (ko)
NZ (1) NZ296003A (ko)
WO (1) WO1996013523A1 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403304B1 (en) 1993-04-06 2002-06-11 Forsyth Dental Infirmary For Children Human osteoclast-specific and -related DNA sequences
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
PL328877A1 (en) 1995-10-30 1999-03-01 Smithkline Beecham Corp Method of inhibiting cathepsin k
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
JP2000500742A (ja) 1995-10-30 2000-01-25 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP0812916A3 (en) * 1996-06-14 1998-12-09 Smithkline Beecham Corporation Cathepsin k gene
WO1998000716A1 (en) * 1996-07-03 1998-01-08 Novadx, Inc. Method for detecting degenerative bone disease
GB9701888D0 (en) * 1997-01-30 1997-03-19 Ciba Geigy Ag Novel methods
US5948669A (en) * 1997-02-26 1999-09-07 Smithkline Beecham Corporation Rat cathepsin K polynucleotide and polypeptide sequence
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6346373B1 (en) * 1999-05-05 2002-02-12 Merck Frosst Canada & Co., Whole cell assay for cathepsin K activity
WO2001000798A2 (en) * 1999-06-25 2001-01-04 Hybritech Incorporated Cloning and expressing of human cathepsin k in mammalian cells
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7071184B2 (en) 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
JP2004535153A (ja) * 2000-10-18 2004-11-25 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
JP4355287B2 (ja) * 2002-06-17 2009-10-28 株式会社ニチレイ ホッコクアカエビ由来の新規なカテプシンｌ様システインプロテアーゼ
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
US7312353B2 (en) 2003-08-21 2007-12-25 Merck Frost Canada & Co. Cathespin cysteine protease inhibitors
US20070015234A1 (en) * 2003-09-23 2007-01-18 Sylvie Desmarais Whole cell assay for inhibitors of cathepsin k
WO2005093421A1 (de) * 2004-03-10 2005-10-06 Biovendor Laboratory Medicine, Inc. Enzymimmunoassay zur bestimmung von cathepsin k
US7029902B2 (en) * 2004-03-26 2006-04-18 Applera Corporation Isolated monkey cathepsin S proteins, nucleic acid molecules encoding monkey cathepsin S proteins, and uses thereof
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
AU2013202011C1 (en) * 2008-03-06 2015-10-01 Halozyme, Inc. In vivo temporal control of activatable matrix-degrading enzymes
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
PT2953948T (pt) 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
WO1997047642A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Cathepsin k gene

Also Published As

Publication number Publication date
EP0783527B1 (en) 2006-02-08
DE69534778D1 (en) 2006-04-20
HU220960B1 (hu) 2002-07-29
US6544767B1 (en) 2003-04-08
EP0783527A4 (en) 1998-12-02
CN1170415A (zh) 1998-01-14
WO1996013523A1 (en) 1996-05-09
EP0783527A1 (en) 1997-07-16
ATE317441T1 (de) 2006-02-15
NO971875L (no) 1997-06-12
JP3670666B2 (ja) 2005-07-13
NO971875D0 (no) 1997-04-23
AU711810B2 (en) 1999-10-21
ES2256849T3 (es) 2006-07-16
NZ296003A (en) 1999-10-28
US20030175937A1 (en) 2003-09-18
CA2203765A1 (en) 1996-05-09
DE69534778T2 (de) 2006-08-17
FI971777A0 (fi) 1997-04-25
AU3968895A (en) 1996-05-23
CN1148382C (zh) 2004-05-05
CA2203765C (en) 2002-04-23
KR100473219B1 (ko) 2005-05-16
FI971777A (fi) 1997-04-25
JPH10512740A (ja) 1998-12-08
HUT77049A (hu) 1998-03-02

Similar Documents

Publication Publication Date Title
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
NZ232742A (en) Yeast heterologous protein production method, vectors, dna constructs and proteins so produced and aprotinin (1-58) so produced
ATE160587T1 (de) Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
EP1090641A3 (en) Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
CA2273196A1 (en) Isolated mammalian monocyte cell genes; related reagents
DK1520860T3 (da) Rekombinant protein PilC, fremgangsmåde til dets fremstilling og anvendelse deraf
ATE317443T1 (de) N-terminal verlängerte proteine exprimiert in hefe
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
HUP9900750A2 (hu) Gén kifejezésére szolgáló promóterek
JPS6467197A (en) Enzymatically inactive and immunologically active b-galatosidase-mutagenic protein, its preparation, immulogical assay of serum protein, and enzyme-immunoassay reagent
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
PT1007627E (pt) Serina protease extracelular
Kawashima et al. Comparison of calpains from rabbit, monkey, human and rat
ATE282701T1 (de) Rekombinante dnase b aus streptococcus pyogenes
WOOD et al. Homology between cellobiose oxidase from Phanerochaete chrysosporium and other proteins

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee